Response to Comment on Foss-Freitas et al. Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy. Diabetes Care 2024;47:653-659.
作者信息
Foss-Freitas Maria C, Broome David T, Oral Elif A
机构信息
Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI.
出版信息
Diabetes Care. 2025 Mar 1;48(3):e32. doi: 10.2337/dci24-0080.
Abstract
摘要
相似文献
1
Response to Comment on Foss-Freitas et al. Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy. Diabetes Care 2024;47:653-659.对关于福斯-弗雷塔斯等人的评论的回应。胰高血糖素样肽1激动剂在家族性部分脂肪营养不良患者回顾性研究中的疗效和安全性。《糖尿病护理》2024年；47:653 - 659。
Diabetes Care. 2025 Mar 1;48(3):e32. doi: 10.2337/dci24-0080.
2
Comment on Foss-Freitas et al. Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy. Diabetes Care 2024;47:653-659.关于福斯-弗雷塔斯等人的评论。胰高血糖素样肽1激动剂在家族性部分脂肪营养不良患者回顾性研究中的疗效和安全性。《糖尿病护理》2024年；47:653 - 659。
Diabetes Care. 2025 Mar 1;48(3):e31. doi: 10.2337/dc24-1777.
3
Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy.胰高血糖素样肽 1 激动剂在家族性部分脂肪营养不良患者回顾性研究中的疗效和安全性。
Diabetes Care. 2024 Apr 1;47(4):653-659. doi: 10.2337/dc23-1614.
4
Safety and effectiveness in an uncontrolled setting of glucagon-like-peptide-1 receptor agonists in patients with familial partial lipodystrophy: Real-life experience from a national reference network.胰高血糖素样肽-1受体激动剂在家族性部分脂肪营养不良患者非对照环境中的安全性和有效性：来自国家参考网络的真实生活经验。
Diabetes Obes Metab. 2025 Apr;27(4):1815-1825. doi: 10.1111/dom.16175. Epub 2025 Jan 20.
5
Insulin secretory defect in familial partial lipodystrophy Type 2 and successful long-term treatment with a glucagon-like peptide 1 receptor agonist.家族性部分脂肪营养不良 2 型的胰岛素分泌缺陷及胰高血糖素样肽 1 受体激动剂的长期成功治疗。
Diabet Med. 2017 Dec;34(12):1792-1794. doi: 10.1111/dme.13527.
6
Comment on Albogami et al. Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344-1352.对阿尔博加米等人的评论。2型糖尿病患者中胰高血糖素样肽1受体激动剂与慢性下呼吸道疾病急性加重。《糖尿病护理》2021年；44:1344 - 1352。
Diabetes Care. 2021 Aug;44(8):e165-e166. doi: 10.2337/dc21-0904. Epub 2021 Jul 20.
7
Response to Comment on Albogami et al. Glucagon-Like Peptide-1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344-1352.对关于阿尔博加米等人的评论的回应。2型糖尿病患者中胰高血糖素样肽-1受体激动剂与慢性下呼吸道疾病加重。《糖尿病护理》2021年；44:1344 - 1352。
Diabetes Care. 2021 Aug;44(8):e167. doi: 10.2337/dci21-0024. Epub 2021 Jul 20.
8
Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.基于肠降血糖素的 2 型糖尿病治疗药物：对疗效、安全性和患者满意度的直接比较的综述。
Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22.
9
Comment on Kutz et al. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care 2023;46:2004-2014.对库茨等人的评论。2型糖尿病中根据虚弱程度比较钠-葡萄糖协同转运蛋白2抑制剂、胰高血糖素样肽-1受体激动剂和二肽基肽酶-4抑制剂的心血管有效性和安全性。《糖尿病护理》2023年；46:2004 - 2014。
Diabetes Care. 2024 Apr 1;47(4):e32-e33. doi: 10.2337/dc23-2420.
10
Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.对关于Kazda等人的评论的回应：胰高血糖素受体拮抗剂LY2409021在2型糖尿病患者中的疗效和安全性评估：12周和24周的2期研究。《糖尿病护理》2016年；39:1241 - 1249。
Diabetes Care. 2016 Nov;39(11):e199-e200. doi: 10.2337/dci16-0030.
本文引用的文献
1
Case report: First Chinese patient with family partial lipodystrophy type 6 due to novel compound heterozygous mutations in the LIPE gene.病例报告：首例因LIPE基因新型复合杂合突变导致的中国家族性部分性脂肪营养不良6型患者。
Front Genet. 2024 Jul 24;15:1417613. doi: 10.3389/fgene.2024.1417613. eCollection 2024.
2
Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy.胰高血糖素样肽 1 激动剂在家族性部分脂肪营养不良患者回顾性研究中的疗效和安全性。
Diabetes Care. 2024 Apr 1;47(4):653-659. doi: 10.2337/dc23-1614.
3
LIPE-related lipodystrophic syndrome: clinical features and disease modeling using adipose stem cells.LIPE 相关脂肪营养不良综合征：临床特征及脂肪干细胞疾病建模。
Eur J Endocrinol. 2021 Jan;184(1):155-168. doi: 10.1530/EJE-20-1013.
4
Homozygous LIPE mutation in siblings with multiple symmetric lipomatosis, partial lipodystrophy, and myopathy.患有多发性对称性脂肪瘤病、部分脂肪营养不良和肌病的兄弟姐妹中的纯合子LIPE突变。
Am J Med Genet A. 2017 Jan;173(1):190-194. doi: 10.1002/ajmg.a.37880. Epub 2016 Nov 11.
Zotero 插件